Literature DB >> 20385354

Prostate cancer: beta control your hormones.

Massimo Loda1, William G Kaelin.   

Abstract

Differentiation status influences the prognosis for localized prostate cancer. In this issue of Cancer Cell, Mak and coworkers describe a signaling pathway involving estrogen receptor beta (ERbeta) that governs whether prostate carcinoma cells maintain an epithelial phenotype or undergo epithelial-mesenchymal transition, suggesting that ERbeta would have prognostic or therapeutic value. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20385354     DOI： 10.1016/j.ccr.2010.03.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  3 in total

1.  Estrogen receptor β sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription.

Authors:  Paul Mak; Cheng Chang; Bryan Pursell; Arthur M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

Review 2.  Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).

Authors:  Izabela Sokolowska; Alisa G Woods; Mary Ann Gawinowicz; Urmi Roy; Costel C Darie
Journal:  Cell Mol Life Sci       Date:  2012-10-18       Impact factor: 9.261

3.  Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).

Authors:  Daniele Campa; Anika Hüsing; Angelika Stein; Lucie Dostal; Heiner Boeing; Tobias Pischon; Anne Tjønneland; Nina Roswall; Kim Overvad; Jane Nautrup Østergaard; Laudina Rodríguez; Núria Sala; Maria-José Sánchez; Nerea Larrañaga; José María Huerta; Aurelio Barricarte; Kay-Tee Khaw; Nicholas Wareham; Ruth C Travis; Naomi E Allen; Pagona Lagiou; Antonia Trichopoulou; Dimitrios Trichopoulos; Domenico Palli; Sabina Sieri; Rosario Tumino; Carlotta Sacerdote; Henk van Kranen; H Bas Bueno-de-Mesquita; Göran Hallmans; Mattias Johansson; Isabelle Romieu; Mazda Jenab; David G Cox; Afshan Siddiq; Elio Riboli; Federico Canzian; Rudolf Kaaks
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.